Dr Reddy's posts big profit rise; Medicaid reimbursement rules delayed;

@FiercePharma: In this week's Sermo survey, almost 50% of MDs say they won't switch patients from Pradaxa. Item | Follow @FiercePharma

> India's Dr Reddy's Laboratories said profit rose 25%  in the fiscal first quarter, almost in line with analysts' estimates, as key drugs helped sales in North America, but it warned about weakness in Germany. Article 

> Despite a September deadline for setting reimbursement for Medicaid prescription drugs, 20 states have not yet developed a new method, according to a report from the inspector general at the Department of Health and Human Services. Piece

> A leading medical advisory panel recommended that all insurers be required to cover contraceptives for women free of charge as one of several preventive services under the new healthcare law. Item

> Japanese drug maker Daiichi Sankyo has introduced its oral anticoagulant drug Lixiana in Japan. News

> India's Dr Reddy's Laboratories has received FDA approval for generic palonosetron hydrochloride injection, used to prevent nausea associated with chemotherapy. Story

> Wholesale shifting of pharmaceutical production to low-cost countries such as India and China is creating environmental impacts "on a scale that can seriously impact the health of humans and animals," says Sweden's Medical Products Agency. Article

> Quest Diagnostics reported weak quarterly lab-testing volume as Americans avoided doctor visits. The company said it plans to reduce its costs by $500 million over the next three years. Story

> Indian drugmaker Piramal Healthcare is in talks to buy Enam Financial's stake in ING Life Insurance, the Economic Times says. Item

Biotech News

@FierceBiotech: Biogen Idec abandoning Weston, plots move to Kendall Sq. News | Follow @FierceBiotech

@JohnCFierce: If this Medco takeover goes through, I have to wonder how many jobs will be cut. Article | Follow @JohnCFierce

> Non-profits share valuable lessons on efficient drug development. Report

> AstraZeneca wins FDA approval for blockbuster hopeful Brilinta. Story

> BioSante inks $39M pact on melanoma vax. Item

> Icon goes on hiring spree as analysts chide CROs on deal risks. Report 

Vaccine News

> Astellas licenses Vical vax for $130M. Article 

> NicVAX failure spells trouble for Nabi. More

> Scripps explores heroin addiction vaccine. Story

> WHO: Flu vaccine production will double by 2015. Report

Manufacturing News

> Silicone particles drive American Regent recall. Article 

> GSK, Lundbeck reveal lean secrets, successes. Report 

> FDA grant aids manufacturing, regulatory science. Story 

> Sun exec: Generic firms will face same tough times as innovators. News

> Fool's manufacturing view akin to Witty's of GSK. Report

And Finally... A recently-discovered gene may be responsible for the proliferation of liver cancer cells, a study found, and researchers hope this finding may offer new ideas for therapy. News

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.